CodePlex

IsoPlexis Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Operating cost, Proteome, GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Health, Isoplexis, Director, U.S. Securities and Exchange Commission, Luminex Corporation, Nasdaq, Technology, Board, Proteomics, CodePlex, SEC, HIV disease progression rates, Board of directors, Nahum, Publication, Cell, The Scientist (magazine), Growth, CEO, Security (finance), Industry, Regulation, COVID-19, Renewable energy, Video game, Pharmaceutical industry, Risk management, Fierce

BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022.
  • Gross margin was 50% for the third quarter of 2022, as compared to 47% for the corresponding prior year period.
  • Total operating expenses were $19.2 million for the third quarter of 2022, representing a 12% reduction from the third quarter of 2021 and a 27% reduction from the second quarter of 2022.
  • IsoPlexis will host a conference call to discuss the third quarter 2022 financial results before market open on Thursday, November 10, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time.

IsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform

Retrieved on: 
Tuesday, September 13, 2022
CodePlex, Adoption, The Scientist (magazine), Health, Risk, Phenotype, Publication, Company, Mouse, IL-7, Proteome, CD19, CEO, Cell, Nasdaq, GLOBE, SEC, HIV disease progression rates, Shanghai Institute of Technology, Scientific Reports, Isoplexis, Vaccine, Fierce, Hematology

With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation.

Key Points: 
  • With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation.
  • The researchers observed that in mice treated with CAR-T cells, cytokine expression measured with IsoPlexis CodePlex platform suggested that IL-7 secretion promoted a Th1 functional phenotype to drive anti-tumor activity more effectively.
  • This initial data generated using IsoPlexis CodePlex solution indicates that the platform can provide key insights into cytokine signatures of CAR-T products to characterize function for improved persistence and potency.
  • This first APAC publication validates IsoPlexis' platform as a powerful tool that provides customers with a new layer of proteomic information, said Jason Ou, President/General Manager, APAC Region at IsoPlexis.

IsoPlexis Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022
U.S. Securities and Exchange Commission, HIV disease progression rates, Isoplexis, Industry, CEO, GLOBE, Forward-looking statement, Private Securities Litigation Reform Act, SEC, Growth, Security (finance), Proteomics, Proteome, Cell, CodePlex, COVID-19, The Scientist (magazine), Operating cost, Nasdaq, RIF, Health, Regulation, Renewable energy, Video game, Pharmaceutical industry, Risk management, Fierce

BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 2022.

Key Points: 
  • BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 2022.
  • Gross margin was 52% for the second quarter of 2022, as compared to 53% for the corresponding prior year period.
  • Total operating expenses were $26.4 million for the second quarter of 2022, which included restructuring expenses of $3.7 million.
  • IsoPlexis will host a conference call to discuss the second quarter 2022 financial results before market open on Wednesday, August 10, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time.

IsoPlexis Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 11, 2022
COVID-19, U.S. Securities and Exchange Commission, Forward-looking statement, The Scientist (magazine), Private Securities Litigation Reform Act, Nasdaq, GLOBE, Security (finance), Industry, Proteomics, SEC, CEO, Regulation, HIV disease progression rates, Growth, CodePlex, Operating cost, Isoplexis, Renewable energy, Video game, Mobile phone, Risk management, Fierce

BRANFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022.

Key Points: 
  • BRANFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter ended March 31, 2022.
  • Gross margin was 52% for the first quarter of 2022, as compared to 51% for the corresponding prior year period.
  • Operating loss was $28.1 million for the first quarter of 2022, as compared to $13.5 million for the corresponding prior year period.
  • IsoPlexis will host a conference call to discuss the first quarter 2022 financial results before market open on Wednesday, May 11, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time.